Adicet Bio
ACET
40 hedge funds and large institutions have $177M invested in Adicet Bio in 2018 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 21 increasing their positions, 6 reducing their positions, and 9 closing their positions.
250% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 6
64% more capital invested
Capital invested by funds: $108M → $177M (+$68.7M)
0.01% less ownership
Funds ownership: 0.38% → 0.37% (-0.01%)
11% less funds holding
Funds holding: 45 → 40 (-5)
56% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
+$12.2M |
| 2 |
Millennium Management
New York
|
+$2.71M |
| 3 |
SCM
Segantii Capital Management
Hong Kong
|
+$1.76M |
| 4 |
BlackRock
New York
|
+$1.75M |
| 5 |
DAM
Deltec Asset Management
New York
|
+$1.57M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$18.1M |
| 2 |
SI
SCP Investment
Orinda,
California
|
-$893K |
| 3 |
JP Morgan Chase
New York
|
-$873K |
| 4 |
AG
Artal Group
Luxembourg
|
-$583K |
| 5 |
VEA
Virtus ETF Advisers
New York
|
-$363K |
ACET Hedge Fund Activity: Q3 2018 in Review
40 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Adicet Bio (ACET) for Q3 2018, worth a combined $177M — up 64% from $108M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of ACET and 4 opened new positions — a net loss of 5 holders — while 6 trimmed existing stakes and 21 added.
The largest buyer was Jennison Associates, adding an estimated $12.2M. The largest seller was Fidelity Investments, exiting entirely with an estimated $18.1M sold.
- 40 institutional investors held Adicet Bio (ACET) as of Q3 2018, down from 45 in Q2 2018.
- Funds reported $177M of Adicet Bio stock for Q3 2018, up 64% quarter-over-quarter.
- 4 funds opened new Adicet Bio positions in Q3 2018 and 9 closed out, a net change of -5 holders.
- The largest Adicet Bio buyer in Q3 2018 was Jennison Associates, an estimated $12.2M added.
- The largest Adicet Bio seller in Q3 2018 was Fidelity Investments, an estimated $18.1M sold.
Based on aggregated 13F filings for Q3 2018.